Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).Hedyeh Ebrahimi, Alex Chehrazi‐Raffle, Tanya B. Dorff et al.|Journal of Clinical Oncology|2025Cited by 1
Long-term clinical outcomes with <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).Sumanta Kumar Pal, T. Dorff, Miguel Zugman et al.|Journal of Clinical Oncology|2026Cited by 0
Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.Salvador Jaime-Casas, Abhishek Tripathi, T. Dorff et al.|Journal of Clinical Oncology|2026Cited by 0
Availability of clinical trials investigating prostate cancer (PC) in the United States (US).Benjamin Mercier, Sumanta Kumar Pal, Miguel Zugman et al.|Journal of Clinical Oncology|2026Cited by 0
First results of a dose-escalation study evaluating <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).Miguel Zugman, Alex Chehrazi-Raffle, T. Dorff et al.|Journal of Clinical Oncology|2026Cited by 0